Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.
about
The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directionsModulating Composition and Metabolic Activity of the Gut Microbiota in IBD PatientsDiet therapy for inflammatory bowel diseases: The established and the newThe gut microbiota and host health: a new clinical frontierThe Intestinal Microbiota in Inflammatory Bowel DiseaseThe role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trialsIntestinal microbiota in health and disease: role of bifidobacteria in gut homeostasisMyD88 mediates the protective effects of probiotics against the arteriolar thrombosis and leukocyte recruitment associated with experimental colitis.Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodateSystematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel diseaseComparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel diseaseChemical characterization and immunomodulatory properties of polysaccharides isolated from probiotic Lactobacillus casei LOCK 0919Probiotic Mix VSL#3 Is Effective Adjunctive Therapy for Mild to Moderately Active Ulcerative ColitisDiet, gut microbes, and the pathogenesis of inflammatory bowel diseases.An update on the use and investigation of probiotics in health and disease.Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel diseasePotential role of nutraceutical compounds in inflammatory bowel diseaseThe Emerging Therapeutic Role of Medical Foods for Gastrointestinal Disorders.Gut microbiota, probiotics, and human healthFecal Microbiota Transplantation: From Clostridium difficile to Inflammatory Bowel Disease.Amelioration of colitis in mouse model by exploring antioxidative potentials of an indigenous probiotic strain of Lactobacillus fermentum Lf1.The Probiotic Mixture VSL#3 Alters the Morphology and Secretion Profile of Both Polarized and Unpolarized Human Macrophages in a Polarization-Dependent Manner.Investigation of the impact of feeding Lactobacillus plantarum CRL 1815 encapsulated in microbially derived polymers on the rat faecal microbiota.Oats and bowel disease: a systematic literature review.Enteric microbiota leads to new therapeutic strategies for ulcerative colitis.Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients.Current and emerging drugs for the treatment of inflammatory bowel disease.Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond.The effect of probiotics and gut microbiota on Th17 cells.Probiotic actions on diseases: implications for therapeutic treatments.Probiotics, prebiotics and the gastrointestinal tract in health and disease.Probiotics, nuclear receptor signaling, and anti-inflammatory pathways.Relationship between gut microbiota and development of T cell associated disease.Gut microbiota, immunity, and disease: a complex relationship.Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation?Emerging science of the human microbiome.Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management.Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease.The gut microbiota and inflammatory bowel disease.Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer.
P2860
Q26745700-4337E84A-5BD2-4939-98D5-8BF168B59156Q26750985-63BD9B53-41E0-4696-AD42-901C60AC3724Q26768564-7A34A0AE-7419-4110-9ABA-3184E1503C17Q26785649-65AAEBE5-2B44-4B3C-B7BD-8BAB2AA91FE1Q26795705-5C288E34-F642-4B5C-B558-0422443E0C12Q27001546-AA010D9A-84CC-47DA-8DB2-1D74B832ED87Q27001712-6FCC46A7-135B-44CC-925B-E30C200AC51DQ27314871-EBDDFC8B-58A2-4CD6-83D5-8BFDA9CDCD64Q28072437-852FDAC7-9AD8-4884-AECC-ADFC0D89509DQ28254207-9C50E43B-AF4E-46CB-8AEF-2999C10B81F1Q28537737-C91757F1-69BA-4E58-80F5-19631AFC4B78Q28828166-51C6DAEA-4873-4F3D-B4D5-1162ABCAB879Q29037475-D434FDB8-35EE-4DDA-AB62-6B6D45F86E4FQ30249313-7D269D74-7571-479F-ADED-9EE246F3890FQ30407565-D88E63DE-03D8-4ED9-89CC-8EEAE3D09EC0Q30570535-F5E3A962-18D1-4A63-A9F2-B0BDAE3710BEQ33572633-4FFA22E4-B042-4118-8378-8C39F778F584Q33595797-0BE31ECC-B1B5-4B25-A2A2-AA79FB60BF2EQ33666412-A5C9F020-EC0F-455D-B54D-1EE420D2A333Q33717111-77E37D5C-F5C0-4207-BD9C-AF6E2D6A7529Q33908943-E9211ABD-6305-4D48-9251-FEDBE1AA22AFQ34092270-2EB77EBF-2DF8-4B1C-9D56-32C72B9F28C7Q34276096-845DF6C0-4DC8-4E6D-90E0-8E7E19BEE43BQ34440935-72886644-59F1-4A9A-A55E-28126F484843Q34499080-07877D34-0903-4DAA-BB24-7E02BAB13176Q34637606-C470A11D-C6AA-48DB-81A0-3BC60AF180FBQ34883210-D6C2C4D4-297C-4CFB-AB95-A3F95593557EQ35000008-DB106A4B-966E-4C1D-B2AF-756EB6546749Q35008169-1E236A0C-570D-4BF2-BC02-EBC8A3D1BB37Q35096915-C9262446-91F2-44B0-838E-62DD4A5C4F1EQ35122167-B5EF72EB-075C-4AC9-8750-EEF12F118F08Q35131051-317F3064-A563-4D9D-9BEF-B0E5E1C30C13Q35134829-DEC6FCFF-A269-41E1-B725-6B74DB2B9E68Q35195785-7140D0AB-F829-4A8E-B7F5-40F913300919Q35195891-9266239F-6971-4381-9E93-CBAD23B702D5Q35205214-7B58CBF9-3841-4F2E-8DBF-3035D732A3F4Q35228714-17833BDF-73CD-4105-B47F-88192BF800F5Q35245299-82C112B5-FD96-49A2-9021-50DAD0B2DA09Q35446516-260CC900-7F02-4B52-BEBB-7D6563599B9AQ35601294-2C390628-E5BD-4326-87A9-6E6AE5370E43
P2860
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Treatment of relapsing mild-to ...... zed, placebo-controlled study.
@ast
Treatment of relapsing mild-to ...... zed, placebo-controlled study.
@en
type
label
Treatment of relapsing mild-to ...... zed, placebo-controlled study.
@ast
Treatment of relapsing mild-to ...... zed, placebo-controlled study.
@en
prefLabel
Treatment of relapsing mild-to ...... zed, placebo-controlled study.
@ast
Treatment of relapsing mild-to ...... zed, placebo-controlled study.
@en
P2093
P2860
P50
P356
P1476
Treatment of relapsing mild-to ...... ized, placebo-controlled study
@en
P2093
Andrea Giglio
Antonio Gasbarrini
Antonio Tursi
Emilio Di Giulio
Giacomo Forti
Gian Marco Giorgetti
Giovanni Brandimarte
Ladislava Sebkova
Maria Antonietta Pistoia
Maria Ester Modeo
P2860
P304
P356
10.1038/AJG.2010.218
P407
P577
2010-06-01T00:00:00Z